MYL2 Polyclonal Antibody

Thus gene encodes the regulatory light chain associated with cardiac myosin beta (or slow) heavy chain. Ca+ triggers the phosphorylation of regulatory light chain that in turn triggers contraction. Mutations in this gene are associated with mid-left ventricular chamber type hypertrophic cardiomyopathy.

The MYL2 Polyclonal Antibody is a highly specific and sensitive antibody that has been designed to detect and quantify the expression of MYL2 protein in various biological samples. This antibody has been extensively validated for its specificity and sensitivity, making it an ideal tool for researchers and clinicians who are interested in studying the role of MYL2 in various physiological and pathological processes.

The MYL2 Polyclonal Antibody has been produced using high-quality immunogens and advanced immunization techniques, ensuring that it recognizes the target protein with high affinity and specificity. This antibody has been extensively characterized using various techniques, including Western blotting, immunohistochemistry, and immunofluorescence, and has been shown to produce highly specific and reproducible results.

The MYL2 Polyclonal Antibody is suitable for use in a wide range of applications, including basic research, drug discovery, and clinical diagnostics. It can be used to study the expression and localization of MYL2 in various tissues and cell types, as well as to investigate the role of MYL2 in various physiological and pathological processes.

Overall, the MYL2 Polyclonal Antibody is a highly reliable and versatile tool that can help researchers and clinicians to better understand the role of MYL2 in various biological processes. Its high specificity and sensitivity make it an ideal choice for a wide range of applications, and its extensive validation ensures that it produces accurate and reproducible results.